Financing ·
Decoys raises $3.85M by reducing warrant exercise price to $3.25 and issuing new warrants
DCOYDecoy Therapeutics Inc.
Decoy Therapeutics Inc. entered into a warrant inducement agreement on September 22, 2026, with an existing institutional investor to exercise outstanding Series B Milestone Warrants for 1,184,434 shares of common stock. The company reduced the exercise price of these Existing Warrants, as well as Series A and Series C warrants, from $5.91 to $3.25 per share. The transaction closed on September 23, 2026, generating approximately $3.85 million in gross proceeds for working capital. As consideration, the investor received new unregistered warrants (New Warrants) to purchase up to 2,368,868 shares at an exercise price of $3.25 per share, exercisable immediately and expiring five years from issuance. Decoy Therapeutics Inc. operates in the biotechnology industry, pioneering Designable Multi-Antivirals (D-MAVs) using its proprietary IMP(3)ACT platform.